WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma

Launched by SHANGHAI PULMONARY HOSPITAL, SHANGHAI, CHINA · Jun 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new method for diagnosing lung adenocarcinoma, which is a type of lung cancer, using advanced technology called deep learning. The goal is to see how well this technology can analyze whole slide images of lung tissue samples to determine the grading of the cancer according to a specific system known as the IASLC grading system. This research is taking place at multiple medical centers and is currently looking for participants.

To be eligible for this trial, participants should be between 18 and 85 years old, have had surgery for lung adenocarcinoma that has been confirmed by a doctor, and must provide written consent to take part. People with multiple lung lesions, poor quality images of their tissue, certain types of adenocarcinoma, or those who have received specific cancer treatments before surgery cannot participate. If you join the trial, you can expect to contribute to important research that could help improve cancer diagnosis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ranging from 18-85 years old;
• • 2. Pathological confirmation of primary lung adenocarcinoma after surgery;
• • 3. Obtained written informed consent.
• Exclusion Criteria:
• • 1. Multiple lung lesions;
• • 2. Poor quality of whole slide images;
• • 3. Mucinous adenocarcinomas and variants;
• • 4. Participants who have received neoadjuvant therapy.